Treatment with sildenafil, a selective PDE5 inhibitor, attenuated LV remodeling in mice subjected to TAC, and was recently shown to confer benefit in patients with stable systolic heart failure and in heart failure patients with preserved ejection fraction and pulmonary hypertension [9], [10], [11]. Here, PDE5A is linked to pulmonary arterial hypertension.